Z. Einbeigi¹, D. Bergström², T. Hatschek³ and M. Malmberg⁴

¹Department of Oncology, Sahlgrenska University Hospital, Göteborg, Sweden. ²Roche AB, Stockholm, Sweden. ³Radiumhemmet, Karolinska University Hospital, Stockholm, Sweden. ⁴Department of Oncology, Helsingborg Hospital, Helsingborg, Sweden.

Abstract

Thirteen patients with untreated metastatic breast cancer received epirubicin 60 mg/m2, paclitaxel 155 mg/m2 (both day 1) and capecitabine 665 mg/m2 twice daily (days 1–14) every 21 days, with intra-patient dose escalation/reduction. Grade 3/4 events were infrequent. Nine patients (69%) achieved an objective response. Median time to progression and overall survival were 6.6 and 23.5 months, respectively.

Discussion
No comments yet...Be the first to comment.

 CONNOTEA  CITEULIKE FACEBOOK LINKED IN